Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.38 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.36 |
| ▸ | KCNQ3 known ✓ | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 known ✓ | O43526 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL349085 | 0.87 | AOC3 (0.40) | ALDH1A1KDM4EPOLBHPGDALOX15 | |
| SCHEMBL349134 | 0.76 | OPRM1 (0.51) | HPGDOPRM1OPRK1 | |
| SCHEMBL13271405 | 0.73 | ALDH1A1 (0.53) | ALDH1A1KDM4EPOLBHPGDALOX15 | |
| SCHEMBL12002619 | 0.72 | ALDH1A1 (0.52) | ALDH1A1KDM4EPOLBHPGDALOX15 | |
| SCHEMBL9966553 | 0.72 | IDO1 (0.44) | ALDH1A1MAPTHSD11B1 | |
| SCHEMBL744117 | 0.71 | OGA (0.45) | ALDH1A1KDM4EPOLBHPGDALOX15 | |
| SCHEMBL13271370 | 0.70 | ALDH1A1 (0.50) | ALDH1A1KDM4EPOLBHPGDALOX15 | |
| SCHEMBL13646218 | 0.70 | OGA (0.46) | ALDH1A1HPGDHSD17B10MAPTUBE2T | |
| SCHEMBL17799112 | 0.70 | HSD11B1 (0.61) | ALDH1A1LMNANPSR1HSD11B1 | |
| Hydrochloric Acid SCHEMBL27676371 | 0.70 | CHRNA7 (0.47) | ALDH1A1KDM4EMAPTUBE2TCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957229-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170334847-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2017-11-23 | — | — | US | disclosed |
| US-9670154-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2963021-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2015-11-19 | — | — | US | disclosed |
| US-9126927-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| EP-1756063-B1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058288-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7776874-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1756063-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | INCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
| EP-1756063-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | disclosed |
| WO-2005110992-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334847-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | OPRM1 612/4885OPRK1 647/4885HSD11B1 1/4885 |
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | OPRM1 612/4885OPRK1 647/4885HSD11B1 1/4885 |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | OPRM1 612/4885OPRK1 647/4885HSD11B1 1/4885 |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | OPRM1 612/4885OPRK1 647/4885HSD11B1 1/4885 |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | HSD11B1, NR3C2, SRD5A1 | OPRM1 947/4885OPRK1 439/4885HSD11B1 1/4885 |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | OPRM1 612/4885OPRK1 647/4885HSD11B1 1/4885 |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | OPRM1 612/4885OPRK1 647/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.